ArticlePaediatric drugs2019
Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.
Article in Paediatric drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Prospective randomized trial of interventions for vincristine-related neuropathic pain.Pediatric blood & cancer · 2020Trial
- Chronic Cancer-Related Pain in Children: A Narrative Review of Multimodal and Family-Centered Palliative Care Approach.Children (Basel, Switzerland) · 2026Review
- Association of analgesic pharmacological effect with pain site in pediatric oncology patients.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Risks and Benefits of Pharmacological Treatment for Pediatric Chronic Non-cancer Pain: When Safety Evidence Lags Behind Prescription Pads.Paediatric drugs · 2025Review
- Causes and management of acute oncological pain: a narrative review.Anaesthesia · 2025Review
- Review
- The Pharmacological Treatment of Neuropathic Pain in Children.Current neuropharmacology · 2024Review
- Multimodal Analgesia in Pediatric Cancer Pain Management: A Retrospective Single-Center Study.Cureus · 2023Article
- Immunopharmacological considerations of general anaesthetics for surgical procedures in the times of COVID-19: Correspondence.Annals of medicine and surgery (2012) · 2023Article
- Interdisciplinary Collaborative Care to Manage Total Pain in Children with Cancer.Children (Basel, Switzerland) · 2022Article
- Evaluation of neuropathic pain with diverse pathophysiologies in childhood cancers.Northern clinics of Istanbul · 2022Article
- High-Dose Gabapentin and Amitriptyline in the Treatment of Refractory Chemotherapy-Induced Peripheral Neuropathy in a Toddler.Journal of medical cases · 2021Article
- Peripheral Nervous System Involvement in Non-Primary Pediatric Cancer: From Neurotoxicity to Possible Etiologies.Journal of clinical medicine · 2021Review
- Refractory symptoms in paediatric palliative care: can ketamine help?Drugs in context · 2021Review
- Diagnosis and Treatment of Chronic Neuropathic and Mixed Pain in Children and Adolescents: Results of a Survey Study amongst Practitioners.Children (Basel, Switzerland) · 2020Article
- Methadone in Cancer Pain.Indian journal of palliative careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Neuropathic pain in pediatric oncology can be caused by distinct lesions or disease processes affecting the somatosensory system, including chemotherapy-related neuronal injury, solid tumor-related involvement of neural structures, post-surgical neuropathic pain-including phantom limb pain and pain after limb-sparing surgery-and the complex circumstances of neuropathic pain at the end of life. Treatment algorithms reflect the general treatment principles applied for adult neuropathic pain, but the dose regimens applied in children are modest and rarely escalated to the maximum doses to optimize analgesic efficacy. Pharmacological management of neuropathic pain should be based on a stepwise intervention strategy, as combinations of medications are the most effective approach. Gabapentinoids and tricyclic antidepressants are recommended as first-line therapy. Methadone, ketamine, and lidocaine may be useful adjuvants in selected patients. Prospective studies extended over a substantial length of time are recommended because of the nature of neuropathic pain as persistent, chronic pain and based on the need for sufficient time to escalate medication dose regimens to full analgesic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.